Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial...
22 insider purchases on record · latest filing 2026-06-11.
Insiders have also filed 81 sale transactions at STTK.